SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 10, 2000
--------------
NOVOSTE CORPORATION
(Exact name of registrant as specified in its charter)
Florida 0-20727 59-2787476
---------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification)
3890 Steve Reynolds Blvd., Norcross, GA 30093
-----------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (770) 717-0904
--------------
(Former name or former address, if changed since last report)
Item 5. Other Events
On March 10, 2000, Novoste Corporation (the "Registrant") issued a press
release announcing that David N. Gill has resigned as the Registrant's Chief
Operating Officer and Chief Financial Officer. A copy of the press release is
attached as Exhibit 99.1 and incorporated by reference herein.
On March 12, 2000, the Registrant issued a press release announcing the
results of the START trial which shows that beta radiation reduces the risk of
repeat blockage and additional treatment for patients suffering from clogged
stents, when compared to patients treated with placebo. A copy of the press
release is attached as Exhibit 99.2 and incorporated by reference herein.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibit 99.1 - Press Release dated March 10, 2000.
Exhibit 99.2 - Press Release dated March 12, 2000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: March 13, 2000
NOVOSTE CORPORATION
-------------------
(Registrant)
By: /S/ WILLIAM A. HAWKINS
----------------------
William A. Hawkins
Chief Executive Officer